65.36
-2.11 (-3.13%)
| 前收盘价格 | 67.47 |
| 收盘价格 | 66.95 |
| 成交量 | 1,284,854 |
| 平均成交量 (3个月) | 2,573,054 |
| 市值 | 8,150,774,784 |
| 价格/销量 (P/S) | 9.17 |
| 股市价格/股市净资产 (P/B) | 55.67 |
| 52周波幅 | |
| 利润日期 | 29 Oct 2025 |
| 营业毛利率 | -53.82% |
| 营业利益率 (TTM) | -54.33% |
| 稀释每股收益 (EPS TTM) | -3.39 |
| 季度收入增长率 (YOY) | 20.80% |
| 流动比率 (MRQ) | 4.11 |
| 营业现金流 (OCF TTM) | -272.26 M |
| 杠杆自由现金流 (LFCF TTM) | -67.71 M |
| 资产报酬率 (ROA TTM) | -18.64% |
| 股东权益报酬率 (ROE TTM) | -4,584.47% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看涨 | 混合的 |
| Diagnostics & Research (全球的) | 看涨 | 混合的 | |
| 股票 | Guardant Health, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.13 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.53% |
| 机构持股比例 | 97.57% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Cadian Capital Management, Lp | 30 Jun 2025 | 3,179,217 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 80.00 (UBS, 22.40%) | 购买 |
| 80.00 (BTIG, 22.40%) | 购买 | |
| 中 | 70.00 (7.10%) | |
| 低 | 60.00 (Scotiabank, -8.20%) | 购买 |
| 平均值 | 71.00 (8.63%) | |
| 总计 | 15 购买 | |
| 平均价格@调整类型 | 57.89 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Evercore ISI Group | 07 Oct 2025 | 68.00 (4.04%) | 购买 | 63.44 |
| Barclays | 02 Oct 2025 | 70.00 (7.10%) | 购买 | 61.46 |
| Canaccord Genuity | 26 Sep 2025 | 75.00 (14.75%) | 购买 | 60.03 |
| BTIG | 25 Sep 2025 | 80.00 (22.40%) | 购买 | 60.18 |
| 22 Sep 2025 | 70.00 (7.10%) | 购买 | 59.78 | |
| Guggenheim | 25 Sep 2025 | 67.00 (2.51%) | 购买 | 60.18 |
| JP Morgan | 25 Sep 2025 | 70.00 (7.10%) | 购买 | 60.18 |
| Leerink Partners | 25 Sep 2025 | 75.00 (14.75%) | 购买 | 60.18 |
| Mizuho | 25 Sep 2025 | 70.00 (7.10%) | 购买 | 60.18 |
| Stifel | 25 Sep 2025 | 70.00 (7.10%) | 购买 | 60.18 |
| TD Cowen | 25 Sep 2025 | 72.00 (10.16%) | 购买 | 60.18 |
| UBS | 25 Sep 2025 | 80.00 (22.40%) | 购买 | 60.18 |
| Wolfe Research | 25 Sep 2025 | 75.00 (14.75%) | 购买 | 60.18 |
| Wells Fargo | 22 Sep 2025 | 72.00 (10.16%) | 购买 | 59.78 |
| Raymond James | 31 Jul 2025 | 61.00 (-6.67%) | 购买 | 40.98 |
| Scotiabank | 31 Jul 2025 | 60.00 (-8.20%) | 购买 | 40.98 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合